Several studies have demonstrated that both single-agent and combination ICI therapies have significantly enhanced clinical efficacy endpoints in locally advanced, metastatic NSCLC and extensive-stage small-cell lung cancer patients without EGFR or ALK gene mutations (239). Here, ALK is linked to non-small cell lung carcinoma.